Clinical Trial Search

Primary: Investigator's Assessment of GL Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS). — 1; 0; 0; 2 Participants

Primary: Incidence Rates of First Episode of Respiratory Syncytial Virus (RSV) Respiratory Tract Infection (RTI) [Period 1] — 7.93 Cases per 100 person-years

Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 16.7; 16.7; 0.0; 33.3 percentage of participants

Primary: Change From Baseline in Height-Standard Deviation Score (H-SDS) of Recombinant Human Growth Hormone (r-hGH) Treated Subjects at Year 3 — 1.39 Standard Deviation Score…

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 163; 74; 7 Participants

Primary: Effect of Surgical Lights on Patient Preference — 37.7; 46.8; 0.00; 1.3 percentage of participants

Primary: Difference in Mean Milligrams of Dietary Sodium in Chosen Foods Pre- and Post- Color Coded Cue Card Intervention — 173.78 milligrams

Primary: Percentage of Participants Reaching Disease Free Survival — 45.8 percentage of participants

Primary: Number of Patients With Atrial Thrombus Diagnosed by Transoesophageal Ultrasound — 48 Participants

Primary: Maximum Severity of Adverse Events After Any Vaccination — 1; 2; 0; 2 Participants — p=0.44

Primary: Rate of Treatment Regimen Completion — 14 Participants

Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 3 — 0; 0 Score on scale

Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants

Primary: Number of Participants With Adverse Events — 10; 4; 1; 20 Participants

Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 2 — 0; 0 Score on scale